Antiphospholipid Antibody Syndrome Treatment Guidelines

Introduction to Treatment

The American Heart Association recommends long-term anticoagulation with vitamin K antagonists (warfarin) with a target INR of 2.0-3.0 for venous thrombosis and potentially higher (INR 3.0-4.0) for arterial thrombosis or recurrent events 1

For patients with venous thrombosis, the American College of Cardiology recommends initiating warfarin therapy with a target INR of 2.0-3.0 1
For asymptomatic patients with positive APLA, low-dose aspirin (75-100 mg daily) is recommended for primary prevention, especially in those with high-risk antibody profiles 1

For women with obstetric APLA syndrome, the American College of Obstetricians and Gynecologists recommends prophylactic treatment with low-dose aspirin (75-100 mg daily) outside of pregnancy 1
During pregnancy, a combination of prophylactic or intermediate-dose unfractionated heparin or prophylactic low-molecular-weight heparin with low-dose aspirin (75-100 mg daily) is recommended by the American College of Chest Physicians 2
For catastrophic APS, aggressive treatment with a combination of anticoagulation, glucocorticoids, and plasma exchange is recommended by the International Society of Nephrology 3

The European Society of Cardiology recommends anti-Xa monitoring for patients on heparin or low-molecular-weight heparin 4
High-risk APLA profile includes triple-positive antibody testing or double-positive or isolated lupus anticoagulant, and these high-risk patients should receive more intensive anticoagulation and closer monitoring 1

Patients with triple-positive antibodies have an annual thrombosis incidence of 5.3% compared to 1.9% with single positive tests, with 40% of thromboembolic events in APLA-positive patients being stroke or TIA 5, 6

The APLASA trial showed no benefit of low-dose aspirin (81 mg/d) over placebo in preventing first thrombotic events in persistently APLA-positive asymptomatic individuals (HR 1.04, 95% CI 0.69-1.56, P=0.83) 5, 6, 7, 8
Asymptomatic APLA-positive individuals have a low overall annual incidence of acute thrombosis and often develop vascular events only when additional thrombotic risk factors are present 5, 6

For patients with systemic lupus erythematosus (SLE) and APLA, a meta-analysis supported a protective role of low-dose aspirin for primary prophylaxis against thrombosis, though bleeding hazard must be considered 9

Minimizing vascular risk factors is always necessary in APLA patients, including smoking cessation and diabetes control 9

Do not initiate warfarin for primary prevention in asymptomatic APLA-positive patients without prior thrombotic events, as the bleeding risk of therapeutic anticoagulation outweighs potential benefit in the primary prevention setting given the relatively low absolute thrombotic risk in asymptomatic carriers 5, 6

For pregnant women with obstetric APLA syndrome, the American College of Chest Physicians recommends prophylactic or intermediate-dose low-molecular-weight heparin (LMWH) or unfractionated heparin combined with low-dose aspirin (75-100 mg daily) throughout pregnancy, with a strength of evidence based on clinical guidelines 10
The American College of Chest Physicians suggests continuing anticoagulation postpartum for 6 weeks with prophylactic- or intermediate-dose LMWH or vitamin K antagonists targeted at INR 2.0-3.0 for women with obstetric APLA syndrome 10
The American College of Chest Physicians advises against using antithrombotic prophylaxis in women with inherited thrombophilia and pregnancy complications who do not have APLA, as this is not supported by evidence 10
The American College of Chest Physicians recommends against screening for inherited thrombophilia in women with pregnancy complications, as APLA screening is what matters for obstetric APS 10